This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Honore, S. Articles by Jordan, M. A. Search for Related Content PubMed PubMed Citation Articles by Honore, S. Articles by Jordan, M. A.

Synergistic Suppression of Microtubule Dynamics by Discodermolide and Paclitaxel in Non-Small Cell Lung Carcinoma Cells

¹ FRE-CNRS 2737, Université de la Méditerranée, Marseille, France; ² Department of Molecular, Cellular and Developmental Biology and Neuroscience Research Institute, University of California, Santa Barbara, California; and ³ Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York

Discodermolide is a new microtubule-targeted antimitotic drug in Phase I clinical trials that, like paclitaxel, stabilizes microtubule dynamics and enhances microtubule polymer mass in vitro and in cells. Despite their apparently similar binding sites on microtubules, discodermolide acts synergistically with paclitaxel to inhibit proliferation of A549 human lung cancer cells (L. Martello et al., Clin. Cancer Res., 6: 1978–1987, 2000). To understand their synergy, we examined the effects of the two drugs singly and in combination in A549 cells and found that, surprisingly, their antiproliferative synergy is related to their ability to synergistically inhibit microtubule dynamic instability and mitosis. The combination of discodermolide and paclitaxel at their antiproliferative IC₅₀s (7 nM for discodermolide and 2 nM for paclitaxel) altered all of the parameters of dynamic instability synergistically except the time-based rescue frequency. For example, together the drugs inhibited overall microtubule dynamicity by 71%, but each drug individually inhibited dynamicity by only 24%, giving a combination index (CI) of 0.23. Discodermolide and paclitaxel also synergistically blocked cell cycle progression at G₂-M (41, 9.6, and 16% for both drugs together, for discodermolide alone, and for paclitaxel alone, respectively; CI = 0.59), and they synergistically enhanced apoptosis (CI = 0.85). Microtubules are unique receptors for drugs. The results suggest that ligands that bind to large numbers of binding sites on an individual microtubule can interact in a poorly understood manner to synergistically suppress microtubule dynamic instability and inhibit both mitosis and cell proliferation, with important consequences for combination clinical therapy with microtubule-targeted drugs.

This article has been cited by other articles:

				S. Honore, A. Pagano, G. Gauthier, V. Bourgarel-Rey, P. Verdier-Pinard, K. Civiletti, A. Kruczynski, and D. Braguer Antiangiogenic vinflunine affects EB1 localization and microtubule targeting to adhesion sites Mol. Cancer Ther., July 1, 2008; 7(7): 2080 - 2089. [Abstract] [Full Text] [PDF]

				T.-C. Chou Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies Pharmacol. Rev., September 1, 2006; 58(3): 621 - 681. [Abstract] [Full Text] [PDF]

				W.-Q. Ding, B. Liu, J. L. Vaught, R. D. Palmiter, and S. E. Lind Clioquinol and docosahexaenoic acid act synergistically to kill tumor cells. Mol. Cancer Ther., July 1, 2006; 5(7): 1864 - 1872. [Abstract] [Full Text] [PDF]

				E. Vassal, C. Barette, X. Fonrose, R. Dupont, E. Sans-Soleilhac, and L. Lafanechere Miniaturization and Validation of a Sensitive Multiparametric Cell-Based Assay for the Concomitant Detection of Microtubule-Destabilizing and Microtubule-Stabilizing Agents J Biomol Screen, June 1, 2006; 11(4): 377 - 389. [Abstract] [PDF]

				B. Pourroy, S. Honore, E. Pasquier, V. Bourgarel-Rey, A. Kruczynski, C. Briand, and D. Braguer Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells. Cancer Res., March 15, 2006; 66(6): 3256 - 3263. [Abstract] [Full Text] [PDF]

				G. S. Huang, L. Lopez-Barcons, B. S. Freeze, A. B. Smith III, G. L. Goldberg, S. B. Horwitz, and H. M. McDaid Potentiation of Taxol Efficacy by Discodermolide in Ovarian Carcinoma Xenograft-Bearing Mice Clin. Cancer Res., January 1, 2006; 12(1): 298 - 304. [Abstract] [Full Text] [PDF]

				K. Kamath, L. Wilson, F. Cabral, and M. A. Jordan {beta}III-Tubulin Induces Paclitaxel Resistance in Association with Reduced Effects on Microtubule Dynamic Instability J. Biol. Chem., April 1, 2005; 280(13): 12902 - 12907. [Abstract] [Full Text] [PDF]

				E. Pasquier, S. Honore, B. Pourroy, M. A. Jordan, M. Lehmann, C. Briand, and D. Braguer Antiangiogenic Concentrations of Paclitaxel Induce an Increase in Microtubule Dynamics in Endothelial Cells but Not in Cancer Cells Cancer Res., March 15, 2005; 65(6): 2433 - 2440. [Abstract] [Full Text] [PDF]